Z. Nickens

发表

Conserved MHC class I-presented dengue virus epitopes identified by immunoproteomics analysis are targets for cross-serotype reactive T-cell response.

M. Jett, R. Philip, G. Sinnathamby, 2012, The Journal of infectious diseases.

Unique and differential protein signatures within the mononuclear cells of HIV-1 and HCV mono-infected and co-infected patients

M. Ricaurte, N. Boukli, R. Philip, 2012, Clinical Proteomics.

EDDR1 is a Potential Immunotherapeutic Antigen in Ovarian, Breast, and Prostate Cancer

A. Secord, P. Block, H. Lyerly, 2011 .

EDDR 1 is a Potential Immunotherapeutic Antigen in Ovarian , Breast , and Prostate Cancer

Secord, P. Block, H. Lyerly, 2011 .

Investigation of ovarian cancer associated sialylation changes in N-linked glycopeptides by quantitative proteomics

R. Philip, Punit Shah, Vivekananda Shetty, 2012, Clinical Proteomics.

MHC Class I-Presented T Cell Epitopes Identified by Immunoproteomics Analysis Are Targets for a Cross Reactive Influenza-Specific T Cell Response

R. Philip, G. Sinnathamby, James S. Testa, 2012, PloS one.

MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response.

H. Lyerly, M. Morse, R. Philip, 2011, Journal of proteomics.

Quantitative immunoproteomics analysis reveals novel MHC class I presented peptides in cisplatin-resistant ovarian cancer cells.

R. Philip, G. Sinnathamby, James S. Testa, 2012, Journal of proteomics.

Investigation of plasma biomarkers in HIV-1/HCV mono- and coinfected individuals by multiplex iTRAQ quantitative proteomics.

R. Philip, G. Sinnathamby, A. Mehta, 2011, Omics : a journal of integrative biology.

Investigation of sialylation aberration in N-linked glycopeptides by lectin and tandem labeling (LTL) quantitative proteomics.

O. J. Semmes, R. Philip, G. Sinnathamby, 2010, Analytical chemistry.

ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers

A. Secord, P. Block, H. Lyerly, 2011, Clinical and experimental immunology.